Europe — EMA
Nintedanib Teva
Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic…
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain non‑small cell lung cancers. By blocking VEGFR, PDGFR and FGFR signaling, it reduces fibroblast proliferation and angiogenesis, helping to slow disease progression.
GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Nintedanib used for?
Nintedanib is used in fibrotic lung diseases and selected oncology settings, targeting pathways that drive fibroblast activity and tumor growth. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays worsening of respiratory symptoms. - Non‑small cell
